
Global Biologic Medications for Psoriasis Market Analysis and Forecast 2025-2031
Description
Summary
According to APO Research, The global Biologic Medications for Psoriasis market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Biologic Medications for Psoriasis is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Biologic Medications for Psoriasis is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The China market for Biologic Medications for Psoriasis is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Biologic Medications for Psoriasis is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Biologic Medications for Psoriasis include AbbVie Biotechnology, Amgen, Boehringer Ingelheim Pharmaceuticals, Bristol-Myers Squibb, Eli Lilly, Janssen Biotech, Kyowa Kirin, LEO Pharma and Novartis, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Biologic Medications for Psoriasis, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Biologic Medications for Psoriasis, also provides the sales of main regions and countries. Of the upcoming market potential for Biologic Medications for Psoriasis, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Biologic Medications for Psoriasis sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Biologic Medications for Psoriasis market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Biologic Medications for Psoriasis sales, projected growth trends, production technology, application and end-user industry.
Biologic Medications for Psoriasis Segment by Company
AbbVie Biotechnology
Amgen
Boehringer Ingelheim Pharmaceuticals
Bristol-Myers Squibb
Eli Lilly
Janssen Biotech
Kyowa Kirin
LEO Pharma
Novartis
Ortho Dermatologics
Pfizer
Samsung Bioepis
Tiefenbacher Pharmaceuticals
UCB
Dalian Yawei Pharmaceutical
Hanwha Chemical
China Medical System
Qilu Pharmaceutical
Biologic Medications for Psoriasis Segment by Type
Interleukin Inhibitors
Tyrosine Kinase Inhibitors
Phosphodiesterase Inhibitors
TNF-α Inhibitors
Other
Biologic Medications for Psoriasis Segment by Application
Retail Pharmacies
Hospital and Clinic
Other
Biologic Medications for Psoriasis Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biologic Medications for Psoriasis market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Biologic Medications for Psoriasis and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biologic Medications for Psoriasis.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Sales (consumption), revenue of Biologic Medications for Psoriasis in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 4: Detailed analysis of Biologic Medications for Psoriasis manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Biologic Medications for Psoriasis sales, revenue, price, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.
Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.
Chapter 10: China type, by application, sales, and revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.
Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 14: The main concluding insights of the report.
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
According to APO Research, The global Biologic Medications for Psoriasis market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Biologic Medications for Psoriasis is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Biologic Medications for Psoriasis is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The China market for Biologic Medications for Psoriasis is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Biologic Medications for Psoriasis is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Biologic Medications for Psoriasis include AbbVie Biotechnology, Amgen, Boehringer Ingelheim Pharmaceuticals, Bristol-Myers Squibb, Eli Lilly, Janssen Biotech, Kyowa Kirin, LEO Pharma and Novartis, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Biologic Medications for Psoriasis, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Biologic Medications for Psoriasis, also provides the sales of main regions and countries. Of the upcoming market potential for Biologic Medications for Psoriasis, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Biologic Medications for Psoriasis sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Biologic Medications for Psoriasis market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Biologic Medications for Psoriasis sales, projected growth trends, production technology, application and end-user industry.
Biologic Medications for Psoriasis Segment by Company
AbbVie Biotechnology
Amgen
Boehringer Ingelheim Pharmaceuticals
Bristol-Myers Squibb
Eli Lilly
Janssen Biotech
Kyowa Kirin
LEO Pharma
Novartis
Ortho Dermatologics
Pfizer
Samsung Bioepis
Tiefenbacher Pharmaceuticals
UCB
Dalian Yawei Pharmaceutical
Hanwha Chemical
China Medical System
Qilu Pharmaceutical
Biologic Medications for Psoriasis Segment by Type
Interleukin Inhibitors
Tyrosine Kinase Inhibitors
Phosphodiesterase Inhibitors
TNF-α Inhibitors
Other
Biologic Medications for Psoriasis Segment by Application
Retail Pharmacies
Hospital and Clinic
Other
Biologic Medications for Psoriasis Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biologic Medications for Psoriasis market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Biologic Medications for Psoriasis and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biologic Medications for Psoriasis.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Sales (consumption), revenue of Biologic Medications for Psoriasis in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 4: Detailed analysis of Biologic Medications for Psoriasis manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Biologic Medications for Psoriasis sales, revenue, price, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.
Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.
Chapter 10: China type, by application, sales, and revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.
Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 14: The main concluding insights of the report.
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
Table of Contents
204 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 Biologic Medications for Psoriasis Market by Type
- 1.2.1 Global Biologic Medications for Psoriasis Market Size by Type, 2020 VS 2024 VS 2031
- 1.2.2 Interleukin Inhibitors
- 1.2.3 Tyrosine Kinase Inhibitors
- 1.2.4 Phosphodiesterase Inhibitors
- 1.2.5 TNF-α Inhibitors
- 1.2.6 Other
- 1.3 Biologic Medications for Psoriasis Market by Application
- 1.3.1 Global Biologic Medications for Psoriasis Market Size by Application, 2020 VS 2024 VS 2031
- 1.3.2 Retail Pharmacies
- 1.3.3 Hospital and Clinic
- 1.3.4 Other
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
- 2 Biologic Medications for Psoriasis Market Dynamics
- 2.1 Biologic Medications for Psoriasis Industry Trends
- 2.2 Biologic Medications for Psoriasis Industry Drivers
- 2.3 Biologic Medications for Psoriasis Industry Opportunities and Challenges
- 2.4 Biologic Medications for Psoriasis Industry Restraints
- 3 Global Market Growth Prospects
- 3.1 Global Biologic Medications for Psoriasis Revenue Estimates and Forecasts (2020-2031)
- 3.2 Global Biologic Medications for Psoriasis Revenue by Region
- 3.2.1 Global Biologic Medications for Psoriasis Revenue by Region: 2020 VS 2024 VS 2031
- 3.2.2 Global Biologic Medications for Psoriasis Revenue by Region (2020-2025)
- 3.2.3 Global Biologic Medications for Psoriasis Revenue by Region (2026-2031)
- 3.2.4 Global Biologic Medications for Psoriasis Revenue Market Share by Region (2020-2031)
- 3.3 Global Biologic Medications for Psoriasis Sales Estimates and Forecasts 2020-2031
- 3.4 Global Biologic Medications for Psoriasis Sales by Region
- 3.4.1 Global Biologic Medications for Psoriasis Sales by Region: 2020 VS 2024 VS 2031
- 3.4.2 Global Biologic Medications for Psoriasis Sales by Region (2020-2025)
- 3.4.3 Global Biologic Medications for Psoriasis Sales by Region (2026-2031)
- 3.4.4 Global Biologic Medications for Psoriasis Sales Market Share by Region (2020-2031)
- 3.5 US & Canada & Mexico
- 3.6 Europe
- 3.7 China
- 3.8 Asia (Excluding China)
- 3.9 South America, Middle East and Africa
- 4 Market Competitive Landscape by Manufacturers
- 4.1 Global Biologic Medications for Psoriasis Revenue by Manufacturers
- 4.1.1 Global Biologic Medications for Psoriasis Revenue by Manufacturers (2020-2025)
- 4.1.2 Global Biologic Medications for Psoriasis Revenue Market Share by Manufacturers (2020-2025)
- 4.1.3 Global Biologic Medications for Psoriasis Manufacturers Revenue Share Top 10 and Top 5 in 2024
- 4.2 Global Biologic Medications for Psoriasis Sales by Manufacturers
- 4.2.1 Global Biologic Medications for Psoriasis Sales by Manufacturers (2020-2025)
- 4.2.2 Global Biologic Medications for Psoriasis Sales Market Share by Manufacturers (2020-2025)
- 4.2.3 Global Biologic Medications for Psoriasis Manufacturers Sales Share Top 10 and Top 5 in 2024
- 4.3 Global Biologic Medications for Psoriasis Sales Price by Manufacturers (2020-2025)
- 4.4 Global Biologic Medications for Psoriasis Key Manufacturers Ranking, 2023 VS 2024 VS 2025
- 4.5 Global Biologic Medications for Psoriasis Key Manufacturers Manufacturing Sites & Headquarters
- 4.6 Global Biologic Medications for Psoriasis Manufacturers, Product Type & Application
- 4.7 Global Biologic Medications for Psoriasis Manufacturers' Establishment Date
- 4.8 Market Competitive Analysis
- 4.8.1 Global Biologic Medications for Psoriasis Market CR5 and HHI
- 4.8.2 2024 Biologic Medications for Psoriasis Tier 1, Tier 2, and Tier 3
- 5 Biologic Medications for Psoriasis Market by Type
- 5.1 Global Biologic Medications for Psoriasis Revenue by Type
- 5.1.1 Global Biologic Medications for Psoriasis Revenue by Type (2020 VS 2024 VS 2031)
- 5.1.2 Global Biologic Medications for Psoriasis Revenue by Type (2020-2031) & (US$ Million)
- 5.1.3 Global Biologic Medications for Psoriasis Revenue Market Share by Type (2020-2031)
- 5.2 Global Biologic Medications for Psoriasis Sales by Type
- 5.2.1 Global Biologic Medications for Psoriasis Sales by Type (2020 VS 2024 VS 2031)
- 5.2.2 Global Biologic Medications for Psoriasis Sales by Type (2020-2031) & (K Units)
- 5.2.3 Global Biologic Medications for Psoriasis Sales Market Share by Type (2020-2031)
- 5.3 Global Biologic Medications for Psoriasis Price by Type
- 6 Biologic Medications for Psoriasis Market by Application
- 6.1 Global Biologic Medications for Psoriasis Revenue by Application
- 6.1.1 Global Biologic Medications for Psoriasis Revenue by Application (2020 VS 2024 VS 2031)
- 6.1.2 Global Biologic Medications for Psoriasis Revenue by Application (2020-2031) & (US$ Million)
- 6.1.3 Global Biologic Medications for Psoriasis Revenue Market Share by Application (2020-2031)
- 6.2 Global Biologic Medications for Psoriasis Sales by Application
- 6.2.1 Global Biologic Medications for Psoriasis Sales by Application (2020 VS 2024 VS 2031)
- 6.2.2 Global Biologic Medications for Psoriasis Sales by Application (2020-2031) & (K Units)
- 6.2.3 Global Biologic Medications for Psoriasis Sales Market Share by Application (2020-2031)
- 6.3 Global Biologic Medications for Psoriasis Price by Application
- 7 Company Profiles
- 7.1 AbbVie Biotechnology
- 7.1.1 AbbVie Biotechnology Comapny Information
- 7.1.2 AbbVie Biotechnology Business Overview
- 7.1.3 AbbVie Biotechnology Biologic Medications for Psoriasis Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.1.4 AbbVie Biotechnology Biologic Medications for Psoriasis Product Portfolio
- 7.1.5 AbbVie Biotechnology Recent Developments
- 7.2 Amgen
- 7.2.1 Amgen Comapny Information
- 7.2.2 Amgen Business Overview
- 7.2.3 Amgen Biologic Medications for Psoriasis Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.2.4 Amgen Biologic Medications for Psoriasis Product Portfolio
- 7.2.5 Amgen Recent Developments
- 7.3 Boehringer Ingelheim Pharmaceuticals
- 7.3.1 Boehringer Ingelheim Pharmaceuticals Comapny Information
- 7.3.2 Boehringer Ingelheim Pharmaceuticals Business Overview
- 7.3.3 Boehringer Ingelheim Pharmaceuticals Biologic Medications for Psoriasis Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.3.4 Boehringer Ingelheim Pharmaceuticals Biologic Medications for Psoriasis Product Portfolio
- 7.3.5 Boehringer Ingelheim Pharmaceuticals Recent Developments
- 7.4 Bristol-Myers Squibb
- 7.4.1 Bristol-Myers Squibb Comapny Information
- 7.4.2 Bristol-Myers Squibb Business Overview
- 7.4.3 Bristol-Myers Squibb Biologic Medications for Psoriasis Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.4.4 Bristol-Myers Squibb Biologic Medications for Psoriasis Product Portfolio
- 7.4.5 Bristol-Myers Squibb Recent Developments
- 7.5 Eli Lilly
- 7.5.1 Eli Lilly Comapny Information
- 7.5.2 Eli Lilly Business Overview
- 7.5.3 Eli Lilly Biologic Medications for Psoriasis Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.5.4 Eli Lilly Biologic Medications for Psoriasis Product Portfolio
- 7.5.5 Eli Lilly Recent Developments
- 7.6 Janssen Biotech
- 7.6.1 Janssen Biotech Comapny Information
- 7.6.2 Janssen Biotech Business Overview
- 7.6.3 Janssen Biotech Biologic Medications for Psoriasis Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.6.4 Janssen Biotech Biologic Medications for Psoriasis Product Portfolio
- 7.6.5 Janssen Biotech Recent Developments
- 7.7 Kyowa Kirin
- 7.7.1 Kyowa Kirin Comapny Information
- 7.7.2 Kyowa Kirin Business Overview
- 7.7.3 Kyowa Kirin Biologic Medications for Psoriasis Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.7.4 Kyowa Kirin Biologic Medications for Psoriasis Product Portfolio
- 7.7.5 Kyowa Kirin Recent Developments
- 7.8 LEO Pharma
- 7.8.1 LEO Pharma Comapny Information
- 7.8.2 LEO Pharma Business Overview
- 7.8.3 LEO Pharma Biologic Medications for Psoriasis Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.8.4 LEO Pharma Biologic Medications for Psoriasis Product Portfolio
- 7.8.5 LEO Pharma Recent Developments
- 7.9 Novartis
- 7.9.1 Novartis Comapny Information
- 7.9.2 Novartis Business Overview
- 7.9.3 Novartis Biologic Medications for Psoriasis Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.9.4 Novartis Biologic Medications for Psoriasis Product Portfolio
- 7.9.5 Novartis Recent Developments
- 7.10 Ortho Dermatologics
- 7.10.1 Ortho Dermatologics Comapny Information
- 7.10.2 Ortho Dermatologics Business Overview
- 7.10.3 Ortho Dermatologics Biologic Medications for Psoriasis Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.10.4 Ortho Dermatologics Biologic Medications for Psoriasis Product Portfolio
- 7.10.5 Ortho Dermatologics Recent Developments
- 7.11 Pfizer
- 7.11.1 Pfizer Comapny Information
- 7.11.2 Pfizer Business Overview
- 7.11.3 Pfizer Biologic Medications for Psoriasis Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.11.4 Pfizer Biologic Medications for Psoriasis Product Portfolio
- 7.11.5 Pfizer Recent Developments
- 7.12 Samsung Bioepis
- 7.12.1 Samsung Bioepis Comapny Information
- 7.12.2 Samsung Bioepis Business Overview
- 7.12.3 Samsung Bioepis Biologic Medications for Psoriasis Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.12.4 Samsung Bioepis Biologic Medications for Psoriasis Product Portfolio
- 7.12.5 Samsung Bioepis Recent Developments
- 7.13 Tiefenbacher Pharmaceuticals
- 7.13.1 Tiefenbacher Pharmaceuticals Comapny Information
- 7.13.2 Tiefenbacher Pharmaceuticals Business Overview
- 7.13.3 Tiefenbacher Pharmaceuticals Biologic Medications for Psoriasis Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.13.4 Tiefenbacher Pharmaceuticals Biologic Medications for Psoriasis Product Portfolio
- 7.13.5 Tiefenbacher Pharmaceuticals Recent Developments
- 7.14 UCB
- 7.14.1 UCB Comapny Information
- 7.14.2 UCB Business Overview
- 7.14.3 UCB Biologic Medications for Psoriasis Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.14.4 UCB Biologic Medications for Psoriasis Product Portfolio
- 7.14.5 UCB Recent Developments
- 7.15 Dalian Yawei Pharmaceutical
- 7.15.1 Dalian Yawei Pharmaceutical Comapny Information
- 7.15.2 Dalian Yawei Pharmaceutical Business Overview
- 7.15.3 Dalian Yawei Pharmaceutical Biologic Medications for Psoriasis Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.15.4 Dalian Yawei Pharmaceutical Biologic Medications for Psoriasis Product Portfolio
- 7.15.5 Dalian Yawei Pharmaceutical Recent Developments
- 7.16 Hanwha Chemical
- 7.16.1 Hanwha Chemical Comapny Information
- 7.16.2 Hanwha Chemical Business Overview
- 7.16.3 Hanwha Chemical Biologic Medications for Psoriasis Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.16.4 Hanwha Chemical Biologic Medications for Psoriasis Product Portfolio
- 7.16.5 Hanwha Chemical Recent Developments
- 7.17 China Medical System
- 7.17.1 China Medical System Comapny Information
- 7.17.2 China Medical System Business Overview
- 7.17.3 China Medical System Biologic Medications for Psoriasis Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.17.4 China Medical System Biologic Medications for Psoriasis Product Portfolio
- 7.17.5 China Medical System Recent Developments
- 7.18 Qilu Pharmaceutical
- 7.18.1 Qilu Pharmaceutical Comapny Information
- 7.18.2 Qilu Pharmaceutical Business Overview
- 7.18.3 Qilu Pharmaceutical Biologic Medications for Psoriasis Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.18.4 Qilu Pharmaceutical Biologic Medications for Psoriasis Product Portfolio
- 7.18.5 Qilu Pharmaceutical Recent Developments
- 8 North America
- 8.1 North America Biologic Medications for Psoriasis Market Size by Type
- 8.1.1 North America Biologic Medications for Psoriasis Revenue by Type (2020-2031)
- 8.1.2 North America Biologic Medications for Psoriasis Sales by Type (2020-2031)
- 8.1.3 North America Biologic Medications for Psoriasis Price by Type (2020-2031)
- 8.2 North America Biologic Medications for Psoriasis Market Size by Application
- 8.2.1 North America Biologic Medications for Psoriasis Revenue by Application (2020-2031)
- 8.2.2 North America Biologic Medications for Psoriasis Sales by Application (2020-2031)
- 8.2.3 North America Biologic Medications for Psoriasis Price by Application (2020-2031)
- 8.3 North America Biologic Medications for Psoriasis Market Size by Country
- 8.3.1 North America Biologic Medications for Psoriasis Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
- 8.3.2 North America Biologic Medications for Psoriasis Sales by Country (2020 VS 2024 VS 2031)
- 8.3.3 North America Biologic Medications for Psoriasis Price by Country (2020-2031)
- 8.3.4 United States
- 8.3.5 Canada
- 8.3.6 Mexico
- 9 Europe
- 9.1 Europe Biologic Medications for Psoriasis Market Size by Type
- 9.1.1 Europe Biologic Medications for Psoriasis Revenue by Type (2020-2031)
- 9.1.2 Europe Biologic Medications for Psoriasis Sales by Type (2020-2031)
- 9.1.3 Europe Biologic Medications for Psoriasis Price by Type (2020-2031)
- 9.2 Europe Biologic Medications for Psoriasis Market Size by Application
- 9.2.1 Europe Biologic Medications for Psoriasis Revenue by Application (2020-2031)
- 9.2.2 Europe Biologic Medications for Psoriasis Sales by Application (2020-2031)
- 9.2.3 Europe Biologic Medications for Psoriasis Price by Application (2020-2031)
- 9.3 Europe Biologic Medications for Psoriasis Market Size by Country
- 9.3.1 Europe Biologic Medications for Psoriasis Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
- 9.3.2 Europe Biologic Medications for Psoriasis Sales by Country (2020 VS 2024 VS 2031)
- 9.3.3 Europe Biologic Medications for Psoriasis Price by Country (2020-2031)
- 9.3.4 Germany
- 9.3.5 France
- 9.3.6 U.K.
- 9.3.7 Italy
- 9.3.8 Russia
- 9.3.9 Spain
- 9.3.10 Netherlands
- 10 China
- 10.1 China Biologic Medications for Psoriasis Market Size by Type
- 10.1.1 China Biologic Medications for Psoriasis Revenue by Type (2020-2031)
- 10.1.2 China Biologic Medications for Psoriasis Sales by Type (2020-2031)
- 10.1.3 China Biologic Medications for Psoriasis Price by Type (2020-2031)
- 10.2 China Biologic Medications for Psoriasis Market Size by Application
- 10.2.1 China Biologic Medications for Psoriasis Revenue by Application (2020-2031)
- 10.2.2 China Biologic Medications for Psoriasis Sales by Application (2020-2031)
- 10.2.3 China Biologic Medications for Psoriasis Price by Application (2020-2031)
- 11 Asia (Excluding China)
- 11.1 Asia Biologic Medications for Psoriasis Market Size by Type
- 11.1.1 Asia Biologic Medications for Psoriasis Revenue by Type (2020-2031)
- 11.1.2 Asia Biologic Medications for Psoriasis Sales by Type (2020-2031)
- 11.1.3 Asia Biologic Medications for Psoriasis Price by Type (2020-2031)
- 11.2 Asia Biologic Medications for Psoriasis Market Size by Application
- 11.2.1 Asia Biologic Medications for Psoriasis Revenue by Application (2020-2031)
- 11.2.2 Asia Biologic Medications for Psoriasis Sales by Application (2020-2031)
- 11.2.3 Asia Biologic Medications for Psoriasis Price by Application (2020-2031)
- 11.3 Asia Biologic Medications for Psoriasis Market Size by Country
- 11.3.1 Asia Biologic Medications for Psoriasis Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
- 11.3.2 Asia Biologic Medications for Psoriasis Sales by Country (2020 VS 2024 VS 2031)
- 11.3.3 Asia Biologic Medications for Psoriasis Price by Country (2020-2031)
- 11.3.4 Japan
- 11.3.5 South Korea
- 11.3.6 India
- 11.3.7 Australia
- 11.3.8 Taiwan
- 11.3.9 Southeast Asia
- 12 South America, Middle East and Africa
- 12.1 SAMEA Biologic Medications for Psoriasis Market Size by Type
- 12.1.1 SAMEA Biologic Medications for Psoriasis Revenue by Type (2020-2031)
- 12.1.2 SAMEA Biologic Medications for Psoriasis Sales by Type (2020-2031)
- 12.1.3 SAMEA Biologic Medications for Psoriasis Price by Type (2020-2031)
- 12.2 SAMEA Biologic Medications for Psoriasis Market Size by Application
- 12.2.1 SAMEA Biologic Medications for Psoriasis Revenue by Application (2020-2031)
- 12.2.2 SAMEA Biologic Medications for Psoriasis Sales by Application (2020-2031)
- 12.2.3 SAMEA Biologic Medications for Psoriasis Price by Application (2020-2031)
- 12.3 SAMEA Biologic Medications for Psoriasis Market Size by Country
- 12.3.1 SAMEA Biologic Medications for Psoriasis Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
- 12.3.2 SAMEA Biologic Medications for Psoriasis Sales by Country (2020 VS 2024 VS 2031)
- 12.3.3 SAMEA Biologic Medications for Psoriasis Price by Country (2020-2031)
- 12.3.4 Brazil
- 12.3.5 Argentina
- 12.3.6 Chile
- 12.3.7 Colombia
- 12.3.8 Peru
- 12.3.9 Saudi Arabia
- 12.3.10 Israel
- 12.3.11 UAE
- 12.3.12 Turkey
- 12.3.13 Iran
- 12.3.14 Egypt
- 13 Value Chain and Sales Channels Analysis
- 13.1 Biologic Medications for Psoriasis Value Chain Analysis
- 13.1.1 Biologic Medications for Psoriasis Key Raw Materials
- 13.1.2 Raw Materials Key Suppliers
- 13.1.3 Manufacturing Cost Structure
- 13.1.4 Biologic Medications for Psoriasis Production Mode & Process
- 13.2 Biologic Medications for Psoriasis Sales Channels Analysis
- 13.2.1 Direct Comparison with Distribution Share
- 13.2.2 Biologic Medications for Psoriasis Distributors
- 13.2.3 Biologic Medications for Psoriasis Customers
- 14 Concluding Insights
- 15 Appendix
- 15.1 Reasons for Doing This Study
- 15.2 Research Methodology
- 15.3 Research Process
- 15.4 Authors List of This Report
- 15.5 Data Source
- 15.5.1 Secondary Sources
- 15.5.2 Primary Sources
- 15.6 Disclaimer
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.